Early immune responses anticipate HIV rebound and precede viral control

ABSTRACT Sustained viral suppression following antiretroviral treatment (ART) cessation is a major goal of HIV cure research1. Rare individuals mount immune responses able to control viral rebound without intervention2,3, however, the earliest moments in which these responses form remain poorly defined. We performed an intensively sampled, prospective analytical treatment interruption (ATI) to study the initial immune response to rebound and to understand its role in defining subsequent virus control. Profiling of peripheral blood mononuclear cells and plasma revealed consistent immune activation prior to systemic rebound, including upregulation of antiviral transcriptional pathways, expansion of CD16++ non-classical monocytes, and increases of inflammatory and antiviral soluble plasma proteins. Individuals with prior viral control (controllers) diverged from non-controllers with a slower slope of rebound, a longer period of immune activity prior to rebound, and engagement of a multifaceted immune program with less systemic inflammation. An intermediate immune signature emerged in a separate ATI cohort of individuals who experienced delayed rebound after receiving broadly neutralizing antibodies4, suggesting that immunotherapy can induce a potentially protective pre-rebound immune response. Together, these data resolve the earliest systemic host immune responses to HIV rebound and demonstrate broad immune differences associated with HIV control phenotypes. Competing Interest Statement M.J.P. serves on a DSMB for American Gene Technologies. S.G.D. reports consulting fees from AbbVie, GSK, Hookipa, American Gene Technologies and Immunocore; owns Tendel stock; and receives research support from Gilead. M.C. served on a Gilead scientific advisory board. A.K.S. reports compensation for consulting and/or SAB membership from Honeycomb Biotechnologies, Cellarity, JnJ, Ochre Bio, Danaher, Parabilis Medicines, Passkey Therapeutics, Conquest Technologies, Relation Therapeutics, IntrECate Biotherapeutics, and Dahlia Biosciences unrelated to this work.